WASHINGTON, DC USA (UroToday.com) - Monica Cardona and colleagues from Lexington, Kentucky and Tulsa, Oklahoma reviewed their experience with oral cyclosporine A for refractory IC/BPS. Thirteen of 19 patients reported a 70% average global improvement in their symptoms in this difficult to treat group. Fatigue, muscle cramping, or laboratory abnormalities curtailed the therapy in a subset of non-responders. The presence of Hunner’s lesion or collagen vascular disease were positive predictors for response.
Presented by Monica Cardona, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA
Reported for UroToday by Philip M. Hanno, MD, MPH, Professor of Urology in the Division of Urology at the Hospital of the University of Pennsylvania.
The opinions expressed in this article are those of the UroToday.com Contributing Editor and do not necessarily reflect the viewpoints of the American Urological Association.
View Full AUA 2011 Meeting Coverage
